November 18–22, 2019
Meet Genedata experts at PEGS Europe in Lisbon, Portugal.
Don't miss the opportunity to see how Genedata solutions efficiently support the whole biopharmaceutical R&D workflow, including screening and protein engineering, expression and purification, characterization and analysis of protein therapeutics, cell line design and development, bioprocess optimization, and quality control of biologicals.
To get more information about Genedata solutions, please contact email@example.com.
Industrializing IO Therapeutic Discovery Platforms: Multispecifics, Engineered TCRs and CAR Ts
Jana Hersch, PhD, Scientific Consultant, Biologics, Genedata
Engineering Antibodies Session
Wednesday, November 20 | 12:45–13:15
Novel classes of bio-molecules are currently evaluated for their use in cancer immunotherapy. Bi- and multi-specific antibodies, Ab-cytokine fusion proteins, non-Ig scaffolds, chimeric antigen receptors (CARs), engineered TCRs and TCR-based bispecific constructs promise significant advantages. However, these highly engineered molecules pose new challenges in design, engineering, cloning, expression, purification, and analytics. Genedata Biologics offers an infrastructure that addresses these challenges and enables the industrialization of these various novel therapeutic platforms.
A Platform Approach to Manage Developability and Manufacturability Risks of Biologics Molecules
Sebastian Kolinko, PhD, Scientific Consultant, Biologics, Genedata
Characterization of Biotherapeutics and Biophysical Characterization of Biotherapeutics Session
Thursday, November 21 | 10:05–10:35
We present a workflow system that enables systematic developability and manufacturability assessments, using both in silico and high throughput analytical confirmatory methods, over the entire biologics R&D process from initial discovery all the way to final candidate selection. We show use cases for mAbs and other complex multi/bispecific formats and discuss building predictive developability models utilizing this system. We also present the underlying molecule and task management needed for analytical organizations to accomplish this.